The first major update since 2018 pushes for earlier screenings, smarter risk tools, and a more personalized path to heart health

Heart disease remains the leading killer of Americans, and for years, the medical community has relied on the same clinical roadmap to fight it. That map just changed.

The American College of Cardiology and the American Heart Association have jointly released an updated guideline on blood cholesterol screening and management — the first comprehensive revision since 2018. Published simultaneously in the Journal of the American College of Cardiology and Circulation, the update marks a significant pivot: away from reactive treatment and toward earlier, more personalized prevention. It was formally presented March 28 at the ACC’s 75th Annual Scientific Session in New Orleans.

The timing is urgent. One in four American adults currently carries elevated levels of low-density lipoprotein cholesterol — commonly known as LDL, or “bad” cholesterol — placing them at increased risk for atherosclerosis, the slow, dangerous narrowing and hardening of the arteries. Left unchecked, excess lipids feed the growth of arterial plaque. When that plaque breaks apart, the fallout can be catastrophic: heart attacks, strokes and emergency procedures to restore circulation.

What the 2026 guideline makes unmistakably clear is that waiting for a crisis is no longer an acceptable strategy.

Cholesterol Prevention: The Case for Starting Earlier

The bedrock principles of heart health have not changed. Eating well, exercising regularly, avoiding tobacco, sleeping sufficiently and managing weight remain foundational. Between 80 and 90 percent of cardiovascular disease is tied, at least in part, to modifiable risk factors — which means lifestyle intervention is not supplementary advice but a primary line of defense.

What has changed is the timeline for action. The updated guideline makes a compelling case for earlier screenings and a broader understanding of who is truly at risk.

For individuals with familial hypercholesterolemia — a hereditary condition that causes dangerously high LDL levels from birth — the guideline now recommends screening beginning around age 9, and potentially earlier depending on family history. Previously, that conversation often started much later.

The guideline also calls for a one-time screening for lipoprotein(a), or Lp(a), a genetically influenced lipid that has historically been overlooked in routine checkups. The numbers are striking: Lp(a) levels at 125 nanomoles per liter raise the risk of heart disease by roughly 40 percent. At 250 nanomoles per liter, that risk doubles.

A New Risk Calculator Built for the Modern Patient

At the center of the guideline’s technical overhaul is a significant upgrade in how risk is measured. The previous standard tool — the Pooled Cohort Equation — estimated a patient’s 10-year cardiovascular risk using data from roughly 26,000 individuals. Its replacement, PREVENT, short for Predicting Risk of Cardiovascular Disease EVENTs, draws on 6.6 million data points and incorporates markers of blood sugar and kidney health for a more complete picture.

Crucially, PREVENT is recommended starting at age 30, a full decade earlier than its predecessor. It also accounts for risk factors that previous models underweighted — among them early menopause, pregnancy complications such as preeclampsia and gestational diabetes, underlying conditions like rheumatoid arthritis, and higher-risk ancestry.

The shift reflects a growing conviction among cardiologists: that catching risk early, when intervention is still preventive rather than corrective, can meaningfully alter a patient’s health trajectory over decades.

Updated LDL Targets and a Broader Treatment Toolkit

The 2026 guideline also redraws the numerical targets for LDL cholesterol management. For adults without existing cardiovascular disease, the optimal LDL level remains below 100 milligrams per deciliter. Those at intermediate risk should now aim below 70 mg/dL. For higher-risk patients, the target drops to below 55 mg/dL. The guideline further establishes benchmarks for non-HDL cholesterol and apolipoprotein B, a cholesterol-bound molecule that offers additional insight into cardiovascular risk.

Statins remain the cornerstone of pharmacological treatment. But the updated guideline expands the recognized toolkit to include ezetimibe, bempedoic acid and injectable PCSK9 monoclonal antibody therapies — options particularly relevant for patients who cannot tolerate statins or need combination treatment to reach target levels.

The guideline also takes care to address populations who have often been left out of the conversation: pregnant and lactating women, adults 75 and older, and those managing diabetes, late-stage chronic kidney disease, HIV or active cancer treatment.

The Road Ahead for Cholesterol Care

An editorial accompanying the guideline signals where the science is heading next. Future updates will likely extend the sub-55 mg/dL LDL target to all patients with at least moderate atherosclerosis — a direction supported by the VESALIUS-CV trial, published in the New England Journal of Medicine after the 2026 guideline had already been finalized. That trial found meaningful benefits from combining lipid-lowering therapies to reach lower LDL thresholds.

The 2026 guideline was developed in collaboration with nine medical organizations — spanning cardiology, preventive medicine, pharmacology, nursing, diabetes care and geriatrics — underscoring that cardiovascular health rarely falls within a single specialty’s domain.

For patients, the directive is straightforward: start the conversation with a clinician sooner rather than later. Whether that means a routine LDL panel, a one-time Lp(a) test or a PREVENT risk score at 30, the goal is the same — to stop cardiovascular disease before it begins.

Source: Johns Hopkins Medicine